Cerebrospinal fluid GAP-43 in early multiple sclerosis

BACKGROUND/OBJECTIVE: Novel biomarkers identifying and predicting disease activity in multiple sclerosis (MS) would be valuable for primary diagnosis and as outcome measures for monitoring therapeutic effects in clinical trials. Axonal loss is present from the earliest stages of MS and correlates wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Rot, U, Sandelius, Å, Emeršič, A, Zetterberg, H, Blennow, K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Original Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6081760/
https://www.ncbi.nlm.nih.gov/pubmed/30094057
http://dx.doi.org/10.1177/2055217318792931

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6081760/
https://www.ncbi.nlm.nih.gov/pubmed/30094057
http://dx.doi.org/10.1177/2055217318792931

Ejemplares similares